Related Experiment Video

Updated: Jun 17, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments

Lisa A Kachnic1, Li Li, Loreen Fournier

  • 1Laboratory of Cellular and Molecular Radiation Oncology, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA. lisa.kachnic@bmc.org

Cancer Letters
|December 26, 2009
PubMed

Insights

Fanconi Anemia (FA) pathway defects in head and neck cancers affect sensitivity to platinum drugs differently than expected. FANCC/FANCD2 mutations confer hypersensitivity, but FANCD2 foci are not reliable biomarkers for platinum drug response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Fanconi Anemia (FA) pathway inactivation occurs in cancers like HNSCC, potentially increasing sensitivity to DNA crosslinking agents.
  • The precise impact of FA pathway defects on cytotoxicity from various chemotherapeutics, including platinum drugs, requires further investigation.

Purpose of the Study:

  • To investigate the differential sensitivity of HNSCC and fibroblast cell lines with FA pathway defects to cisplatin and oxaliplatin.
  • To explore potential biomarkers for predicting platinum drug hypersensitivity in tumors with specific FA pathway mutations.

Main Methods:

  • Utilized a panel of HNSCC and fibroblast cell lines with defined Fanconi Anemia (FA) pathway mutations (FANCC, FANCD2, FANCA).
  • Assessed cellular sensitivity to platinum-based chemotherapy agents (cisplatin, oxaliplatin) and mitomycin C.
  • Examined FANCD2 mono-ubiquitination and the formation of FANCD2/RAD51 subnuclear foci as potential biomarkers.

Main Results:

  • FANCC- and FANCD2-mutant cells exhibited greater hypersensitivity to platinum drugs compared to FANCA-mutant cells.
  • FANCD2 mono-ubiquitination, a marker of FA core complex activity, was not essential for platinum resistance.
  • Platinum hypersensitivity was dissociable from mitomycin C hypersensitivity, suggesting distinct underlying mechanisms.
  • FANCD2 or RAD51 subnuclear foci did not serve as reliable biomarkers for platinum hypersensitivity in FANCC/FANCD2-mutant cells.

Conclusions:

  • The Fanconi Anemia (FA) pathway is not linear, comprising functional subcomplexes with distinct roles.
  • Specific FA pathway defects, particularly in FANCC and FANCD2, can lead to platinum drug hypersensitivity in HNSCC.
  • Development of predictive biomarkers for stratifying patients with FA pathway defects to specific chemotherapies is crucial.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...